Celldex Therapeutics, Inc.

NasdaqCM:CLDX Stock Report

Market Cap: US$1.6b

Celldex Therapeutics Future Growth

Future criteria checks 2/6

Celldex Therapeutics is forecast to grow earnings and revenue by 26.1% and 64.6% per annum respectively. EPS is expected to grow by 27.2% per annum. Return on equity is forecast to be -169.5% in 3 years.

Key information

26.1%

Earnings growth rate

27.2%

EPS growth rate

Biotechs earnings growth26.8%
Revenue growth rate64.6%
Future return on equity-169.5%
Analyst coverage

Good

Last updated02 Jan 2025

Recent future growth updates

Recent updates

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Jun 07
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jun 05
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Jul 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Apr 21
An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

Feb 27
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth

We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Sep 07
We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate

Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder

Jul 21

Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement

Jul 14

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

May 25
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Feb 03
Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?

Celldex: Pipeline Of Drug Candidates Is Worth A Look

Feb 01

Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers

Sep 23

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Sep 15
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

NasdaqCM:CLDX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202736-272-217-2555
12/31/20263-274-234-1907
12/31/20254-227-165-17010
12/31/20247-160-157-14310
9/30/202410-154-160-158N/A
6/30/20248-150-123-121N/A
3/31/20246-145-121-119N/A
12/31/20237-141-109-107N/A
9/30/20234-125-98-97N/A
6/30/20233-113-114-113N/A
3/31/20233-119-110-108N/A
12/31/20222-112-106-104N/A
9/30/20221-106-98-96N/A
6/30/20221-100-79-78N/A
3/31/20224-77-69-67N/A
12/31/20215-71-62-61N/A
9/30/20218-72-53-52N/A
6/30/20219-66-48-47N/A
3/31/20215-64-48-46N/A
12/31/20207-60-42-40N/A
9/30/20205-48-48-46N/A
6/30/20204-46-47-45N/A
3/31/20205-46-46-45N/A
12/31/20194-51-47-46N/A
9/30/20194-50-52-51N/A
6/30/20195-46-55-54N/A
3/31/20197-50-61-60N/A
12/31/201810-151-76-75N/A
9/30/201811-146-80-79N/A
6/30/201814-165N/A-89N/A
3/31/201815-177N/A-93N/A
12/31/201713-93N/A-100N/A
9/30/201711-121N/A-101N/A
6/30/20179-125N/A-100N/A
3/31/20177-128N/A-113N/A
12/31/20167-129N/A-113N/A
9/30/20167-129N/A-106N/A
6/30/20166-131N/A-110N/A
3/31/20166-132N/A-101N/A
12/31/20155-127N/A-99N/A
9/30/20155-126N/A-107N/A
6/30/20155-122N/A-106N/A
3/31/20154-118N/A-102N/A
12/31/20144-118N/A-102N/A
9/30/20143-108N/A-94N/A
6/30/20143-103N/A-85N/A
3/31/20142-94N/A-82N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLDX's revenue (64.6% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: CLDX's revenue (64.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CLDX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 10:56
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Celldex Therapeutics, Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Kristen KluskaCantor Fitzgerald & Co.
David LebowitzCitigroup Inc